Latest Intelligence on Pharmaceuticals in Canada

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Flu remedies: out in the cold

Published By Datamonitor
08 Nov 2000
CommentWire
CommentWire

Inex/GSK: the growing importance of drug delivery

GSK will foot the bill for Inex's development work. In a market where drug delivery is becoming as important as the compound itself, the deal represents a good chance for GSK to boost the sales and life expectancy of its drug. Inex, meanwhile, should gain significant opportunities by partnering with a leading pharmaceutical company.

Published By Datamonitor
26 Nov 2001
CommentWire
CommentWire

ID Biomedical: prevention is better than cure

If ID's Streptococcus vaccine proves to be effective, it has a strong chance of commercial success. There is a strong opportunity to develop vaccines for bacterial disease, as vaccination is considered preferable to antibiotic treatment. ID is at a particular advantage in this area, due to its Proteosomes nasal drug delivery technology.

Published By Datamonitor
16 Apr 2002
CommentWire
CommentWire

AstraZeneca: blockbuster status remains distant for Iressa

AstraZeneca's [AZN.L] Iressa was billed as one of a new class of anti-tumor agents that would revolutionize the treatment of lung cancer. However, to date the drug has been disappointing and approvals continue to be for third-line treatment. If Iressa is to reach blockbuster status, it must reach patients as a first line therapy.

Published By Datamonitor
05 Jan 2004
CommentWire
CommentWire

GW Pharmaceuticals: high expectations for cannabis drug

GW Pharmaceuticals [GWP.L] and Bayer Healthcare [BAY.F] have submitted a New Drug Submission for Sativex, a cannabis-based medicine for the symptomatic treatment of multiple sclerosis (MS) and neuropathic pain, to Health Canada. This move will help generate optimism regarding Sativex, offering renewed hope for manufacturers and patients alike.

Published By Datamonitor
13 May 2004
CommentWire
CommentWire

Sanofi-Aventis/BMS: patent victory pending?

Apotex and Dr Reddy's have been challenging Sanofi [SNY] and Bristol-Myers Squibb (BMS) [BMY] over a Plavix patent concerning a 'parent molecule', which expires in 2011. However, the fact that the challenge was rejected in Canada is a positive outcome for Sanofi and BMS and indicates that they could also win the case in the more important US market.

Published By Datamonitor
23 Mar 2005
CommentWire
CommentWire

Cardiome: heart failure

Cardiome Pharma has revealed that its phase II study investigating the safety and efficacy of oxypurinol in heart failure patients failed to meet both the primary and secondary endpoints, sparking debate over oxypurinol's future. Indeed, it looks like Cardiome may now have to put all of its eggs into one basket, depending on its other pipeline drug, RSD1235.

Published By Datamonitor
17 Aug 2005
CommentWire
CommentWire

Cel-Sci: Multikine increases treatment options for head and neck cancer

Canadian regulators' approval of a phase III trial examining Multikine in head and neck cancer is a clear fillip for manufacturer Cel-Sci, as the drug is the firm's lead product. However, Multikine is still likely struggle to compete with rival product Erbitux, which is in late-stage development and has already demonstrated a survival advantage in head and neck cancer.

Published By Datamonitor
24 Aug 2005
CommentWire
CommentWire

Shire: comeback conundrums

Canadian regulators have agreed to allow Shire's ADHD drug Adderall XR to return to the market following its temporary withdrawal earlier this year. This is good news for Shire as reinstatement of Adderall XR in Canada will help to re-establish both the drug's reputation and its share of the Canadian ADHD market. However, looking at the outlook for the drug in a wider context, it is no panacea.

Published By Datamonitor
26 Aug 2005
CommentWire
CommentWire

Migenix: infectious ambitions in hepatitis

Migenix' CEO recently announced the company's plans to initiate a clinical combination clinical trial with celgosivir in treatment-naive hepatitis C patients. While this is further good news for the experimental drug's development, direct HCV inhibitors are currently perceived as the most promising developmental drug class, and competition in the hepatitis C market is thus expected to be fierce.

Published By Datamonitor
25 Jan 2006

« | 1 | 2 | » »|

No help is available.